Then, we adopted the CRISPR-Cas9 system to specifically inhibit ABCB1 at the DNA level in osteosarcoma MDR cells, and further determined the effects of ABCB1 knockout on reversing drug resistance in osteosarcoma MDR cells. This evidence concerns the gene ABCB1 and osteosarcoma.